Tenon Medical Inc
For the period ended Dec 31, 2023. Filed Mar 29, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Mar 29, 2024
TNON$1.74-0.6%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 8. Consolidated Statements of Cash Flows
Consolidated Statements of Cash Flows
(In thousands)
| Years Ended December 31, | ||
|---|---|---|
| 2023 | 2022 | |
| Cash Flows from Operating Activities | ||
| Net loss | $(15,581) | $(18,917) |
| Adjustments to reconcile net loss to net cash used in operating activities: | ||
| Unrealized loss on investments | — | (16) |
| Non-cash interest expense | — | 362 |
| Stock-based compensation expense | 4,145 | 2,897 |
| Common stock issued for services | — | 1,561 |
| Depreciation and amortization | 199 | 78 |
| Loss on write-off of fixed assets | — | 77 |
| Amortization of operating right-of-use asset | 227 | 211 |
| Increase (decrease) in cash resulting from changes in: | ||
| Accounts receivable | (290) | (152) |
| Inventory | (139) | (227) |
| Prepaid expenses and other assets | (301) | (57) |
| Accounts payable | (117) | 72 |
| Accrued expenses | (99) | 2,288 |
| Operating lease liability | (227) | (202) |
| Net cash used in operating activities | (12,183) | (12,025) |
| Cash Flows from Investing Activities | ||
| Sales of short-term investments | 6,996 | 8,079 |
| Purchases of short-term investments | (493) | (10,116) |
| Purchases of property and equipment | (361) | (847) |
| Net cash provided by (used in) investing activities | 6,142 | (2,884) |
| Cash Flows from Financing Activities | ||
| Proceeds from issuance of common stock and warrants, net of issuance costs | 4,808 | 14,139 |
| Proceeds from issuance of common stock, net of issuance costs | 495 | — |
| Proceeds from issuance of convertible notes payable | 1,250 | — |
| Proceeds from exercise of warrants | 258 | — |
| Deferred offering costs | (509) | (25) |
| Net cash provided by financing activities | 6,302 | 14,114 |
| Effect of foreign currency translation on cash flow | 38 | 7 |
| Net Increase (Decrease) in Cash and Cash Equivalents | 299 | (788) |
| Cash and Cash Equivalents at Beginning of Year | 2,129 | 2,917 |
| Cash and Cash Equivalents at End of Year | $2,428 | $2,129 |
| Cash at End of Year | $2,428 | $480 |
| Cash Equivalents at End of Year | $— | $1,649 |
| Supplemental Disclosures of Cash Flow Information | ||
| Cash paid during the year for: | ||
| Interest | $— | $— |
| Income taxes | $— | $— |
| Non-cash investment and financing activities: | ||
| Common stock issued upon conversion of preferred stock | $— | $13,639 |
| Common stock issued upon conversion of debt | $— | $13,868 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.